Genprex (NASDAQ:GNPX) Rating Increased to Sell at Wall Street Zen

Wall Street Zen upgraded shares of Genprex (NASDAQ:GNPX) to a sell rating in a research note issued to investors on Saturday morning.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Genprex in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Genprex Stock Down 23.7%

NASDAQ GNPX opened at $0.36 on Friday. Genprex has a 12 month low of $0.14 and a 12 month high of $3.97. The firm’s fifty day moving average price is $0.23 and its 200 day moving average price is $0.26.

Genprex (NASDAQ:GNPX) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.71) by $0.54. Equities analysts anticipate that Genprex will post -5.7 EPS for the current year.

About Genprex

Genprex, Inc, a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes.